The TEG® system, using a small blood sample of whole blood, documents the interaction of platelets with protein coagulation cascade from the time of placing the blood in the TEG® analyzer until initial fibrin formation, clot rate strengthening, and fibrin-platelet bonding via GPIIb/IIIa, to eventual clot lysis. Time, rate, strength, and stability of clot will determine whether the patient has normal, hypo-, or hypercoagulable hemostasis, and will provide an indication of treatment necessary to normalize it. 

Each TEG® parameter, R,K,a,MA and LY30, represents a different aspect of patient hemostasis.  However, due to the interactive nature of hemostasis, these parameters are interrelated.